ESMO 2018 Congress Munich, Germany – 19 Oct – 23 Oct 2018 Myriam Fabre, PhD. (Oncomatryx R&D Director) presents the poster: OMTX705, a powerful stroma-targeting ADC to treat invasive tumors with
Oncomatryx will attend BIO EUROPE SPRING 2018, the essential appointment in biotechnology BIO EUROPE SPRING 2018 March 12-14, 2018 Amsterdam, The Netherlands https://ebdgroup.knect365.com/bioeurope- If you are also attending this event and you would like
Oncomatryx will attend BIO 2017, the Global Event for Biotechnology.
ENTURE SUMMIT WEST 2017 February 28 – March 1 2017 Mountain View, CA USA David Raksin, our Business Development Director will be a Presenting role as a Top Innovator in
Antibody Drug Conjugates Against Tumor Stroma: The Beginning of The End? by Mirella Zulueta, Business Development Director at Oncomatryx The potential of a technology trigger Despite many research breakthroughs
Oncomatryx will attend BIOEUROPE. November 7-9. Cologne. FOCUS. November 9-12. Cyprus. If you are also attending any of these events and you would like to meet us please fill
Oncomatryx at the “Cancer Metabolism and the Tumour Microenvironment Conference”. 9-12, November. Paphos, Cyprus. Myriam Fabre, PhD. (Oncomatryx R&D Director) will attend the conference as speaker: TARGETING TUMOR MICROENVIRONMENT TO
Poster presentation at the 2nd ASPIC International Congress. 28-29 April, 2016. Porto. Portugal. We are pleased to inform you that Enrique De Alava team from Hospital Virgen del Rocío, Sevilla, Spain,
